Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus NUZYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus NUZYRA.
DECLOMYCIN vs NUZYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
Omadacycline is a aminomethylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
200 mg intravenously once on day 1, then 100 mg IV once daily; or 200 mg orally once on day 1, then 100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Terminal elimination half-life is approximately 17-21 hours; supports once-daily dosing.
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Fecal (approximately 76%) as unchanged drug; renal (approximately 14%) as unchanged drug; biliary excretion is minimal.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic